{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:11:33Z","timestamp":1777421493146,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacologic and clinical profile of risankizumab-rzaa in the treatment of Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      A PubMed search was performed from inception to August 2022 using keywords\n                      <jats:italic toggle=\"yes\">risankizumab<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">risankizumab-rzaa<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">interleukin-23 inhibitor<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">Crohn\u2019s disease<\/jats:italic>\n                      . Information was obtained from package inserts as well as published abstracts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Phase 2 and 3 studies plus relevant literature on risankizumab-rzaa pharmacologic and clinical profile were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Risankizumab-rzaa approval was based on ADVANCE, MOTIVATE, and FORTIFY. In these 3 phase 3 studies involving patients with moderate to severe CD, risankizumab-rzaa, when compared with placebo, resulted in clinical remission and endoscopic response in a significantly higher proportion of patients in both the induction and maintenance phase. In addition, risankizumab-rzaa met the secondary endpoints of clinical response, endoscopic improvement, corticosteroid-free remission, and mucosal healing. Common adverse events noted include nasopharyngitis, arthralgia, headache, abdominal pain, and nausea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Risankizumab-rzaa is the first selective IL-23 inhibitor approved for CD and provides an additional therapeutic option for patients, particularly those who have been previously treated with other advanced inflammatory bowel disease therapies. Additional studies are required to determine how to best position risankizumab-rzaa in both bio-na\u00efve and bio-experienced patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Risankizumab-rzaa is the most recent therapeutic advance for CD. It has a selective mechanism of action with a similar safety profile comparable with other currently approved advanced therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221130450","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T06:28:14Z","timestamp":1665210494000},"page":"579-584","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn\u2019s Disease"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-1784","authenticated-orcid":false,"given":"David","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Sheridan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-9506","authenticated-orcid":false,"given":"Shubha","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Digestive Disease &amp; Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.04.010."},{"key":"e_1_3_2_3_2","unstructured":"Lewis RT Maron DJ. Efficacy and complications of surgery for Crohn\u2019s disease. Gastroenterol Hepatol (N Y). 2010;6(9):587-596. Accessed September 28 2022. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21088749."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043335."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11413315."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602773."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199710093371502."},{"key":"e_1_3_2_14_2","unstructured":"Skyizi (Risankizumab-rzaa) [package insert]. North Chicago IL: Abbvie Inc; 2019."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30233-4."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0704-z."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4."},{"key":"e_1_3_2_20_2","unstructured":"Skyrizi Cost. Date unknown. Accessed June 29 2022. https:\/\/www.skyrizi.com\/crohns\/about-skyrizi\/cost."},{"key":"e_1_3_2_21_2","unstructured":"Skyrizi Access Support. Date unknown. Accessed June 29 2022. https:\/\/www.skyrizihcp.com\/gastroenterology\/crohns-disease\/access-and-support."},{"key":"e_1_3_2_22_2","unstructured":"MyAbbvie Assist. Accessed June 29 2022. https:\/\/www.abbvie.com\/patients\/patient-assistance.html."},{"key":"e_1_3_2_23_2","unstructured":"Study comparing intravenous (IV)\/subcutaneous (SC) risankizumab to IV\/SC ustekinumab to assess change in Crohn\u2019s disease activity index (CDAI) in adult participants with moderate to severe Crohn\u2019s disease (CD) (SEQUENCE). Published 2022. Accessed August 12 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04524611."},{"key":"e_1_3_2_24_2","unstructured":"Kashani A Schwartz DA. The expanding role of anti-IL-12 and\/or anti-IL-23 antibodies in the treatment of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2019;15(5):255-265. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31360139."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221130450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221130450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221130450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:09Z","timestamp":1777375029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221130450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/10600280221130450"],"URL":"https:\/\/doi.org\/10.1177\/10600280221130450","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}